Details
- Autor(en) / Beteiligte
- Titel
- Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma
- Ist Teil von
- PloS one, 2010-03, Vol.5 (3), p.e9750-e9750
- Ort / Verlag
- United States: Public Library of Science
- Erscheinungsjahr
- 2010
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Glioblastoma multiforme is the most lethal brain tumor with limited therapeutic options. Antigens expressed on the surface of malignant cells are potential targets for antibody-mediated gene/drug delivery. In this study, we investigated the ability of genetically modified human mesenchymal stem cells (hMSCs) expressing a single-chain antibody (scFv) on their surface against a tumor specific antigen, EGFRvIII, to enhance the therapy of EGFRvIII expressing glioma cells in vivo. The growth of U87-EGFRvIII was specifically delayed in co-culture with hMSC-scFvEGFRvIII. A significant down-regulation was observed in the expression of pAkt in EGFRvIII expressing glioma cells upon culture with hMSC-scFvEGFRvIII vs. controls as well as in EGFRvIII expressing glioma cells from brain tumors co-injected with hMSC-scFvEGFRvIII in vivo. hMSC expressing scFvEGFRvIII also demonstrated several fold enhanced retention in EGFRvIII expressing flank and intracranial glioma xenografts vs. control hMSCs. The growth of U87-EGFRvIII flank xenografts was inhibited by 50% in the presence of hMSC-scFvEGFRvIII (p<0.05). Moreover, animals co-injected with U87-EGFRvIII and hMSC-scFvEGFRvIII intracranially showed significantly improved survival compared to animals injected with U87-EGFRvIII glioma cells alone or with control hMSCs. This survival was further improved when the same animals received an additional dosage of hMSC-scFvEGFRvIII two weeks after initial tumor implantation. Of note, EGFRvIII expressing brain tumors co-injected with hMSCs had a lower density of CD31 expressing blood vessels in comparison with control tumors, suggesting a possible role in tumor angiogenesis. The results presented in this study illustrate that genetically modified MSCs may function as a novel therapeutic vehicle for malignant brain tumors.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1932-6203eISSN: 1932-6203DOI: 10.1371/journal.pone.0009750Titel-ID: cdi_plos_journals_1289397166
- Format
- –
- Schlagworte
- Analysis, Angiogenesis, Animals, Antibodies, Antigens, Blood vessels, Bone marrow, Brain, Brain cancer, Brain Neoplasms - metabolism, Brain Neoplasms - pathology, Brain Neoplasms - therapy, Brain tumors, Breast cancer, Cell culture, Cell growth, Cell Line, Tumor, Cell Proliferation, Cell survival, Chains, Chemokines, Coculture Techniques, Coinjection, Cytokines, Drug delivery, Drug delivery systems, Epidermal growth factor, Flow Cytometry - methods, Gene amplification, Genetic engineering, Genetic modification, Genetically modified organisms, Genetics and Genomics/Gene Therapy, Glioblastoma, Glioblastoma multiforme, Glioma, Glioma - metabolism, Glioma - pathology, Glioma - therapy, Glioma cells, Gliomas, Growth, Health aspects, Humans, Immunoglobulins, Implantation, Kinases, Mesenchymal stem cells, Mesenchymal Stromal Cells - cytology, Mesenchyme, Metastasis, Mice, Mutation, Neoplasm Transplantation, Neovascularization, Pathologic, Neurological Disorders/Neuro-Oncology, Oncology/Neuro-Oncology, Phosphorylation, Platelet Endothelial Cell Adhesion Molecule-1 - biosynthesis, Receptor, Epidermal Growth Factor - genetics, Skin & tissue grafts, Stem cell transplantation, Stem cells, Surgical implants, Survival, Tumors, Viral antibodies, Xenografts